Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd News
Feb 25, 2026 - businesswire.com
LSB Industries, Inc. Reports Operating Results for the 2025 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2026
Feb 11, 2026 - businesswire.com
LSB Industries, Inc. Schedules 2025 Fourth Quarter and Full Year Results Release for Wednesday, February 25th and Conference Call for Thursday, February 26th
LakeShore Biopharma Co., Ltd Quantitative Score
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
LakeShore Biopharma Co., Ltd Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
LakeShore Biopharma Co., Ltd Financials
Table Compare
Compare LSB metrics with: | |||
|---|---|---|---|
Earnings & Growth | LSB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LSB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LSB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LSB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
LakeShore Biopharma Co., Ltd Income
LakeShore Biopharma Co., Ltd Balance Sheet
LakeShore Biopharma Co., Ltd Cash Flow
LakeShore Biopharma Co., Ltd Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
LakeShore Biopharma Co., Ltd Executives
| Name | Role |
|---|---|
| Hui Shao | President, Chief Business Officer & Vice Chairman |
| Yuan Liu | Head of Vaccine Research |
| Zenaida Reynoso Mojares | Chief Medical Officer |
| Wang Xu | Chief Executive Officer & Director |
| Rui Yu | Chief Financial Officer & Director |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Hui Shao | President, Chief Business Officer & Vice Chairman | 1968 | -- | |
| Yuan Liu | Head of Vaccine Research | 1987 | -- | |
| Zenaida Reynoso Mojares | Chief Medical Officer | 1959 | -- | |
| Wang Xu | Chief Executive Officer & Director | Male | 1971 | -- |
| Rui Yu | Chief Financial Officer & Director | Female | 1975 | -- |